Program
pozelimab
Also written as “Pozelimab”, “REGN3918” and “Pozelimab + Cemdisiran”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Geographic Atrophy, led by Regeneron Pharmaceuticals.
Furthest: phase 4, since Aug 19, 202514 company-led studies, 5 open or runningNext primary completion: Jul 3, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 145 open or running | phase 4since Aug 19, 2025 | Apr 5, 2017 | Jul 3, 2028phase 1 · NCT07230834 |
Also a collaborator on its studies: Alnylam Pharmaceuticals.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03115996 · 56 enrolled · United Kingdom
- May 8, 2019Phase 2 study in Hemoglobinuria, ParoxysmalNCT03946748 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
- Nov 11, 2019Phase 3 study in Hemoglobinuria, ParoxysmalNCT04162470 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
- Dec 20, 2019Phase 3 study in Protein-Losing EnteropathiesNCT04209634 · 10 enrolled · United States, Thailand, Turkey (Türkiye)
- Jul 13, 2020Phase 1 study in Healthy VolunteerNCT04491838 · 40 enrolled · Belgium
- Oct 21, 2020Phase 1 study in HealthyNCT04601844 · 19 enrolled · Belgium
- Mar 19, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04811716 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
- Apr 23, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04888507 · 6 enrolled · United Kingdom
- Jun 17, 2021Phase 1 study in HealthyNCT04940364 · 30 enrolled · United Kingdom
- Sep 27, 2021Phase 3 study in Myasthenia GravisNCT05070858 · 288 enrolled · United States, Belgium, Brazil and more
- Feb 6, 2023Phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921 · 202 planned · Brazil, Canada, Colombia and more
- Aug 13, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745 · 35 planned · Brazil, Canada, Italy and more
- Aug 19, 2025Phase 4 study in Protein-Losing EnteropathiesNCT07142343 · 5 planned · Turkey (Türkiye)
- Nov 13, 2025Phase 1 study in Geographic AtrophyNCT07230834 · 54 planned · United States, Georgia, Puerto Rico and more
Ahead
- Jul 3, 2028Primary completion: phase 1 study in Geographic AtrophyNCT07230834
- Oct 10, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921
- Jan 18, 2030Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745
- Feb 12, 2030Primary completion: phase 4 study in Protein-Losing EnteropathiesNCT07142343
TargetBeta
C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230834Geographic Atrophy · United States, Georgia, Puerto Rico and more | 1 | Recruiting | Jul 3, 2028 | 54 |
| NCT07142343Protein-Losing Enteropathies · Turkey (Türkiye) | 4 | Recruiting | Feb 12, 2030 | 5 |
| NCT07154745Hemoglobinuria, Paroxysmal · Brazil, Canada, Italy and more | 3 | Recruiting | Jan 18, 2030 | 35 |
| NCT05744921Hemoglobinuria, Paroxysmal · Brazil, Canada, Colombia and more | 3 | Recruiting | Oct 10, 2028 | 202 |
| NCT05070858Myasthenia Gravis · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jul 8, 2025 | 288 |
| NCT04940364Healthy · United Kingdom | 1 | Completed | Jun 22, 2022 | 30 |
| NCT04888507Hemoglobinuria, Paroxysmal · United Kingdom | 2 | Completed | May 5, 2022 | 6 |
| NCT04811716Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more | 2 | Completed | Oct 25, 2022 | 24 |
| NCT04601844Healthy · Belgium | 1 | Completed | Jul 23, 2021 | 19 |
| NCT04491838Healthy Volunteer · Belgium | 1 | Completed | Mar 5, 2021 | 40 |
| NCT04209634Protein-Losing Enteropathies · United States, Thailand, Turkey (Türkiye) | 3 | Completed | Nov 9, 2021 | 10 |
| NCT04162470Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more | 3 | Terminated | Apr 7, 2022 | 24 |
| NCT03946748Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more | 2 | Completed | Jun 9, 2021 | 24 |
| NCT03115996Healthy Volunteers · United Kingdom | 1 | Completed | Aug 31, 2018 | 56 |
How it is read
Names in the registry
- “Pozelimab”, 10 entries
- “REGN3918”, 3 entries
- “Pozelimab + Cemdisiran”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 6 studies
- Myasthenia Gravis, 1 study
- Geographic Atrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.